Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Virus Adaptation and Selection Following Challenge of Animals Vaccinated against Classical Swine Fever Virus.

Fahnøe U, Pedersen AG, Johnston CM, Orton RJ, Höper D, Beer M, Bukh J, Belsham GJ, Rasmussen TB.

Viruses. 2019 Oct 10;11(10). pii: E932. doi: 10.3390/v11100932.

2.

Genome Sequence of an Unknown Subtype of Hepatitis C Virus Genotype 6: Another Piece for the Taxonomic Puzzle.

Pedersen MS, Mollerup S, Nielsen LG, Jenssen H, Bukh J, Schønning K.

Microbiol Resour Announc. 2019 Oct 17;8(42). pii: e01030-19. doi: 10.1128/MRA.01030-19.

3.

HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen.

Filskov J, Andersen P, Agger EM, Bukh J.

Sci Rep. 2019 Oct 1;9(1):14085. doi: 10.1038/s41598-019-50365-z.

4.

Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.

Wolfisberg R, Holmbeck K, Nielsen L, Kapoor A, Rice CM, Bukh J, Scheel TKH.

J Virol. 2019 Sep 12;93(19). pii: e00733-19. doi: 10.1128/JVI.00733-19. Print 2019 Oct 1.

PMID:
31292246
5.

Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.

Keck ZY, Pierce BG, Lau P, Lu J, Wang Y, Underwood A, Bull RA, Prentoe J, Velázquez-Moctezuma R, Walker MR, Luciani F, Guest JD, Fauvelle C, Baumert TF, Bukh J, Lloyd AR, Foung SKH.

PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May.

6.

Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations.

Prentoe J, Velázquez-Moctezuma R, Augestad EH, Galli A, Wang R, Law M, Alter H, Bukh J.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):10039-10047. doi: 10.1073/pnas.1822002116. Epub 2019 Apr 30.

7.

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky JM, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM.

Hepatology. 2019 Sep;70(3):771-787. doi: 10.1002/hep.30647. Epub 2019 Jun 5.

8.

Genetic and structural insights into broad neutralization of hepatitis C virus by human VH1-69 antibodies.

Tzarum N, Giang E, Kong L, He L, Prentoe J, Augestad E, Hua Y, Castillo S, Lauer GM, Bukh J, Zhu J, Wilson IA, Law M.

Sci Adv. 2019 Jan 2;5(1):eaav1882. doi: 10.1126/sciadv.aav1882. eCollection 2019 Jan.

9.

In Vitro Neutralization Assay Using Cultured Hepatitis C Virus.

Prentoe J, Bukh J.

Methods Mol Biol. 2019;1911:433-439. doi: 10.1007/978-1-4939-8976-8_29.

PMID:
30593643
10.

Full-Length Open Reading Frame Amplification of Hepatitis C Virus.

Fahnøe U, Bukh J.

Methods Mol Biol. 2019;1911:85-91. doi: 10.1007/978-1-4939-8976-8_5.

PMID:
30593619
11.

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals.

Pihl AF, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM.

Sci Rep. 2018 Nov 30;8(1):17505. doi: 10.1038/s41598-018-35010-5.

12.

Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.

Velázquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J.

J Virol. 2019 Feb 5;93(4). pii: e01909-18. doi: 10.1128/JVI.01909-18. Print 2019 Feb 15.

13.

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.

Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SBN, Schønning K, Bukh J, Gottwein JM.

J Hepatol. 2019 Mar;70(3):388-397. doi: 10.1016/j.jhep.2018.10.031. Epub 2018 Nov 3.

PMID:
30395912
14.

Hypervariable Region 1 in Envelope Protein 2 of Hepatitis C Virus: A Linchpin in Neutralizing Antibody Evasion and Viral Entry.

Prentoe J, Bukh J.

Front Immunol. 2018 Sep 27;9:2146. doi: 10.3389/fimmu.2018.02146. eCollection 2018. Review.

15.

Hepatitis C Virus-Escape Studies for Human Monoclonal Antibody AR4A Reveal Isolate-Specific Resistance and a High Barrier to Resistance.

Velázquez-Moctezuma R, Galli A, Law M, Bukh J, Prentoe J.

J Infect Dis. 2019 Jan 1;219(1):68-79. doi: 10.1093/infdis/jiy481.

PMID:
30102355
16.
17.

Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies.

Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J.

Virology. 2018 Sep;522:177-192. doi: 10.1016/j.virol.2018.05.020. Epub 2018 Jul 20.

18.

Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.

Sølund C, Andersen ES, Mössner B, Laursen AL, Røge BT, Kjær MS, Gerstoft J, Christensen PB, Pedersen MS, Schønning K, Fahnøe U, Bukh J, Weis N.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1177-1186. doi: 10.1097/MEG.0000000000001192.

PMID:
29994874
19.

Ribavirin-induced mutagenesis across the complete open reading frame of hepatitis C virus genotypes 1a and 3a.

Mejer N, Fahnøe U, Galli A, Ramirez S, Benfield T, Bukh J.

J Gen Virol. 2018 Aug;99(8):1066-1077. doi: 10.1099/jgv.0.001095. Epub 2018 Jun 21.

PMID:
29927371
20.

A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus.

Pedersen MS, Fahnøe U, Hansen TA, Pedersen AG, Jenssen H, Bukh J, Schønning K.

J Clin Virol. 2018 Aug;105:49-56. doi: 10.1016/j.jcv.2018.05.012. Epub 2018 Jun 1.

PMID:
29886373
21.

Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation.

Sølund C, Hallager S, Pedersen MS, Fahnøe U, Ernst A, Krarup HB, Røge BT, Christensen PB, Laursen AL, Gerstoft J, Bélard E, Madsen LG, Schønning K, Pedersen AG, Bukh J, Weis N; DANHEP group.

Scand J Gastroenterol. 2018 Jun - Jul;53(7):849-856. doi: 10.1080/00365521.2018.1467963. Epub 2018 May 2.

PMID:
29720023
22.

Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.

Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J.

Sci Rep. 2018 Mar 15;8(1):4619. doi: 10.1038/s41598-018-22620-2.

23.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.

Riva L, Song OR, Prentoe J, Helle F, L'homme L, Gattolliat CH, Vandeputte A, Fénéant L, Belouzard S, Baumert TF, Asselah T, Bukh J, Brodin P, Cocquerel L, Rouillé Y, Dubuisson J.

J Virol. 2018 Apr 27;92(10). pii: e01982-17. doi: 10.1128/JVI.01982-17. Print 2018 May 15.

24.

Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies.

Bartenschlager R, Baumert TF, Bukh J, Houghton M, Lemon SM, Lindenbach BD, Lohmann V, Moradpour D, Pietschmann T, Rice CM, Thimme R, Wakita T.

Virus Res. 2018 Mar 15;248:53-62. doi: 10.1016/j.virusres.2018.02.016. Epub 2018 Mar 2. Review.

25.

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.

Pham LV, Ramirez S, Gottwein JM, Fahnøe U, Li YP, Pedersen J, Bukh J.

Gastroenterology. 2018 Jun;154(8):2194-2208.e12. doi: 10.1053/j.gastro.2018.02.017. Epub 2018 Feb 15.

PMID:
29454794
26.

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J.

Gastroenterology. 2018 Apr;154(5):1435-1448. doi: 10.1053/j.gastro.2017.12.015. Epub 2017 Dec 22.

PMID:
29274866
27.

The clinical relevance of qualitatively distinct subtypes of depression.

Kessing LV, Bukh JD.

World Psychiatry. 2017 Oct;16(3):318-319. doi: 10.1002/wps.20461. No abstract available.

28.

Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae.

Smith DB, Meyers G, Bukh J, Gould EA, Monath T, Scott Muerhoff A, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P, Becher P.

J Gen Virol. 2017 Aug;98(8):2106-2112. doi: 10.1099/jgv.0.000873. Epub 2017 Aug 8.

29.

Rate and predictors of conversion from unipolar to bipolar disorder: A systematic review and meta-analysis.

Kessing LV, Willer I, Andersen PK, Bukh JD.

Bipolar Disord. 2017 Aug;19(5):324-335. doi: 10.1111/bdi.12513. Epub 2017 Jul 17. Review.

PMID:
28714575
30.

Mouse models of acute and chronic hepacivirus infection.

Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM.

Science. 2017 Jul 14;357(6347):204-208. doi: 10.1126/science.aal1962.

31.

Genetic variants in 5-HTTLPR, BDNF, HTR1A, COMT, and FKBP5 and risk for treated depression after cancer diagnosis.

Suppli NP, Bukh JD, Moffitt TE, Caspi A, Johansen C, Tjønneland A, Kessing LV, Dalton SO.

Depress Anxiety. 2017 Sep;34(9):845-855. doi: 10.1002/da.22660. Epub 2017 Jun 7.

32.

Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes.

Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM.

J Virol. 2017 Jun 26;91(14). pii: e00130-17. doi: 10.1128/JVI.00130-17. Print 2017 Jul 15.

33.

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.

Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00037-17. doi: 10.1128/AAC.00037-17. Print 2017 Jun.

34.

Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.

Velázquez-Moctezuma R, Law M, Bukh J, Prentoe J.

PLoS Pathog. 2017 Feb 23;13(2):e1006214. doi: 10.1371/journal.ppat.1006214. eCollection 2017 Feb.

35.

ICTV Virus Taxonomy Profile: Flaviviridae.

Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff S, Pletnev A, Rico-Hesse R, Smith DB, Stapleton JT, Ictv Report Consortium.

J Gen Virol. 2017 Jan;98(1):2-3. doi: 10.1099/jgv.0.000672.

36.

Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family.

Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, Muerhoff AS, Pletnev A, Rico-Hesse R, Stapleton JT, Simmonds P.

J Gen Virol. 2016 Nov;97(11):2894-2907. doi: 10.1099/jgv.0.000612. Epub 2016 Sep 28.

37.
38.

Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.

Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J.

Gastroenterology. 2016 Nov;151(5):973-985.e2. doi: 10.1053/j.gastro.2016.07.013. Epub 2016 Jul 22.

PMID:
27453546
39.

Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Prentoe J, Velázquez-Moctezuma R, Foung SK, Law M, Bukh J.

Hepatology. 2016 Dec;64(6):1881-1892. doi: 10.1002/hep.28705. Epub 2016 Aug 9.

40.

Diagnostic Stability of Comorbid Personality Disorders Among Patients Fully or Partially Remitted From First-Episode Depression: A 5-Year Follow-Up Study.

Bukh JD, Bech P, Kessing LV.

J Pers Disord. 2017 Apr;31(2):208-220. doi: 10.1521/pedi_2016_30_253. Epub 2016 Jun 20.

PMID:
27322576
41.

Personality and the Long-Term Outcome of First-Episode Depression: A Prospective 5-Year Follow-Up Study.

Bukh JD, Andersen PK, Kessing LV.

J Clin Psychiatry. 2016 Jun;77(6):e704-10. doi: 10.4088/JCP.15m09823.

PMID:
27232945
42.

The validity of dysthymia to predict clinical depressive symptoms as measured by the Hamilton Depression Scale at the 5-year follow-up of patients with first episode depression.

Bech P, Kessing LV, Bukh JD.

Nord J Psychiatry. 2016 Nov;70(8):563-6. doi: 10.1080/08039488.2016.1180712. Epub 2016 May 16.

PMID:
27181030
43.

Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.

Pedersen J, Lundbo LF, Krarup H, Bukh J, Weis N.

J Med Virol. 2016 Oct;88(10):1791-803. doi: 10.1002/jmv.24537. Epub 2016 May 16.

PMID:
27027386
44.

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3563-78. doi: 10.1128/AAC.02929-15. Print 2016 Jun.

45.

Functional analysis of microRNA-122 binding sequences of hepatitis C virus and identification of variants with high resistance against a specific antagomir.

Li YP, Van Pham L, Uzcategui N, Bukh J.

J Gen Virol. 2016 Jun;97(6):1381-1394. doi: 10.1099/jgv.0.000445. Epub 2016 Mar 2.

PMID:
26935756
46.

Rates and predictors of remission, recurrence and conversion to bipolar disorder after the first lifetime episode of depression--a prospective 5-year follow-up study.

Bukh JD, Andersen PK, Kessing LV.

Psychol Med. 2016 Apr;46(6):1151-61. doi: 10.1017/S0033291715002676. Epub 2016 Jan 8.

PMID:
26743873
47.

HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.

Prentoe J, Verhoye L, Velázquez Moctezuma R, Buysschaert C, Farhoudi A, Wang R, Alter H, Meuleman P, Bukh J.

Gut. 2016 Dec;65(12):1988-1997. doi: 10.1136/gutjnl-2015-310300. Epub 2015 Nov 20.

48.

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.

Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM.

Antimicrob Agents Chemother. 2015 Dec;59(12):7426-36. doi: 10.1128/AAC.01953-15. Epub 2015 Sep 21.

49.

5-HTTLPR and use of antidepressants after colorectal cancer including a meta-analysis of 5-HTTLPR and depression after cancer.

Suppli NP, Bukh JD, Moffitt TE, Caspi A, Johansen C, Albieri V, Tjønneland A, Kessing LV, Dalton SO.

Transl Psychiatry. 2015 Sep 1;5:e631. doi: 10.1038/tp.2015.121.

50.

Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge.

Bukh J, Engle RE, Faulk K, Wang RY, Farci P, Alter HJ, Purcell RH.

J Virol. 2015 Sep;89(17):9128-32. doi: 10.1128/JVI.01194-15. Epub 2015 Jun 17.

Supplemental Content

Support Center